Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan-doxycycline dual therapy vs bismuth-containing quadruple therapy as rescue treatment for Helicobacter pylori
ChiCTR2500115106Phase 4Not yet recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vonoprazan, doxycycline, furazolidone, bismuth subsalicylate and amoxicillin in Helicobacter pylori infection (2 arms), sponsored by Nanjing First Hospital. Primary endpoint: Hp eradication rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
vonoprazandoxycyclinefurazolidonebismuth subsalicylateamoxicillin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2500115106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115106.